News Release

March 29, 2021
Sysmex Corporation

Sysmex Continues to Evolve Its Hematology Product Portfolio

- Flagship Model XR-Series and Compact 3-part WBC Differential Model XQ-Series to Be Rolled Out Sequentially -

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) today announced the launch of its next-generation flagship model in the hematology field, the XR-Series Automated Hematology Analyzer, and a compact 3-part WBC differential model, the XQ-Series Automated Hematology Analyzer.
Starting with the launch of these products, Sysmex will continue to evolve its hematology product portfolio to help optimize operations at testing laboratories in line with regional characteristics and facility needs.

Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer ("XN-Series") in 2011, combining modules for blood count, smear preparation, automated digital cell morphology analysis and sample sorting to offer a broad range of system options tailored to each customer's environment, and has captured the largest market share worldwide.

Sysmex continues to evolve its product portfolio in the field of hematology with the aim of "providing more valuable test results and creating a laboratory environment that can make the best use of these results." To begin, Sysmex will launch its next-generation flagship model in the hematology field, the XR-Series Automated Hematology Analyzer ("XR-Series") and a compact 3-part WBC differential model, the XQ-Series Automated Hematology Analyzer ("XQ-Series").
The XR-Series, the successor to the XN-Series, was developed based on the following three pillars of "Operational Value (improvement in the efficiency of laboratory operations)," "Managerial Value (optimization of testing laboratory management)," and "Clinical Value (enhancing the clinical value of laboratory results)." In addition to improving the throughput by up to 10%, the XR-Series reduces the number of microscopy examinations required and improves the efficiency of laboratory operations by optimizing the counting of immature granulocytes[1] and immature platelets, as well as optimizing the flagging function.[2] Inheriting the modular concept, the XR-Series can be combined with modules for smear preparation, automatic digital cell morphology analysis, and sample sorting and archive, providing medium- to large-scale hospitals and clinical laboratories with a wide range of options. Sysmex will first introduce the XR-1000/XR-2000 models and then gradually expand products and services.

The XQ-Series, the successor to the XP-Series Automated Hematology Analyzer, has increased throughput to 70 tests per hour and improved the efficiency of laboratory operations by enhancing the differential WBC count performance through digital waveform processing. We have also adopted the technology of our flagship model and employed a highly robust, maintainable interface that is

compatible with high-end instrument. By doing this, we aim to increase our market share and our presence in the market for 3-part WBC differential analyzers, particularly in emerging countries.

By connecting these two products with Caresphere™, customers can easily and remotely monitor and analyze the operational status of their instrument and the entire laboratory, thereby further improving the efficiency of day-to-day laboratory operations.

As a front-runner, Sysmex will strive to provide new value by proactively utilizing advanced technologies and continuously engaging in research and development.

Product Overview

JMDN:	Blood cell counter (35476000)
Product name:	XR-Series Automated Hematology Analyzer (Medical Device Marketing Notification No.: 28B1X10014000008)
Configuration name:	XR-1000/XR-2000
Areas covered:	All regions
Marketing authorization holder:	Sysmex Corporation
Date of launch:	Japan – April 2021 Overseas – To be launched sequentially after obtaining regulatory approval in each country

Appearance:

XR-1000

XR-2000

JMDN:	Blood cell counter (35476000)
Product name:	XQ-Series Automated Hematology Analyzer (Medical Device Marketing Notification No.: 28B1X10014000007)
Model name:	XQ-320
Areas covered:	All regions
Marketing authorization holder:	Sysmex Corporation
Date of launch:	Japan – March 2021 Overseas – To be launched sequentially after obtaining regulatory approval in each country

Appearance:

XQ-320

References

Press release dated April 5, 2018: "Sysmex Launches Caresphere™, a New Network Solution -Supporting the Intelligent Use of Information for the Healthcare of the Future, Where the Use of Information is Accelerating-"
https://www.sysmex.co.jp/en/news/2018/180405.html

Press release dated March 18, 2019: "Sysmex Launches Caresphere™ LWS, a Laboratory Information System -Further Enhancing Clinical Testing Efficiency through a New Caresphere™ Solution-"
https://www.sysmex.co.jp/en/news/2019/190318.html

Press release dated September 19, 2019: "Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management -Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution-"
https://www.sysmex.co.jp/en/news/2019/190919.html

Terminology

1 Granulocytes:
Granulocytes are white blood cells that contain bactericidal substances called granules in the cytoplasm and can be divided into three types: neutrophils, eosinophils, and basophils. Immature granulocytes are granulocytes that have not matured and do not normally appear in peripheral blood but can be found in peripheral blood during bone marrow recovery, in cases of severe infections, in bone marrow metastatic cancer, and in myeloid leukemia.

2 Flagging function:
A function that alerts the user to the potential occurrence of a specific abnormal sample, such as when a numerical value outside the reference value range set in the instrument beforehand is detected. This function is not directly linked to diagnosis and is used only as supplementary data for testing.